S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
How major US stock indexes fared Thursday, 4/18/2024
3 Steel Stocks Could Soar on New China Tariffs
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
These are the Top 4 Stocks for Buybacks in 2024
Can Netflix Stock Continue Into All-Time Highs After Earnings?
NASDAQ:CDXS

Codexis (CDXS) Stock Price, News & Analysis

$2.80
+0.04 (+1.45%)
(As of 04/18/2024 ET)
Today's Range
$2.71
$2.90
50-Day Range
$2.69
$4.65
52-Week Range
$1.45
$4.91
Volume
615,947 shs
Average Volume
573,549 shs
Market Capitalization
$196.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.80

Codexis MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
142.9% Upside
$6.80 Price Target
Short Interest
Bearish
3.39% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-3.67
Upright™ Environmental Score
News Sentiment
0.00mentions of Codexis in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.60) to ($0.63) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.42 out of 5 stars

Medical Sector

398th out of 918 stocks

Industrial Organic Chemicals Industry

11th out of 18 stocks

CDXS stock logo

About Codexis Stock (NASDAQ:CDXS)

Codexis, Inc. discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.

CDXS Stock Price History

CDXS Stock News Headlines

You’re invited: Biggest crypto event of 2024
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
AQST,CDXS and STI are among after hour movers
You’re invited: Biggest crypto event of 2024
During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.
Benchmark Upgrades Codexis (CDXS)
Stifel Nicolaus Keeps Their Buy Rating on Codexis (CDXS)
Q4 2023 Codexis Inc Earnings Call
Recap: Codexis Q4 Earnings
Biotech Rallied Strongly On Exclusive Licensing Agreement
Codexis Shares Up 31% on Roche Licensing Agreement
Codexis Q4 2023 Earnings Preview
See More Headlines
Receive CDXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Codexis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
4/18/2024
Next Earnings (Estimated)
5/02/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Industrial organic chemicals
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:CDXS
CUSIP
19200510
Employees
174
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.80
High Stock Price Target
$10.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+142.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
6 Analysts

Profitability

Net Income
$-76,240,000.00
Net Margins
-108.69%
Pretax Margin
-108.59%

Debt

Sales & Book Value

Annual Sales
$70.14 million
Book Value
$1.24 per share

Miscellaneous

Free Float
65,875,000
Market Cap
$196.84 million
Optionable
Optionable
Beta
2.01
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Stephen George Dilly MBBS (Age 64)
    Ph.D., President, CEO & Director
    Comp: $753.61k
  • Mr. Kevin Norrett M.B.A. (Age 51)
    M.S., Chief Operating Officer
    Comp: $507.28k
  • Ms. Margaret Fitzgerald J.D. (Age 53)
    Chief Legal and Compliance Officer, General Counsel & Secretary
    Comp: $300.03k
  • Mr. Sriram Ryali M.B.A. (Age 42)
    Chief Financial Officer
  • Carrie McKim
    Director of Investor Relations
  • Ms. Karen Frechou-Armijo
    Senior VP & Head of Human Resources
  • Dr. Stefan Lutz Ph.D.
    Senior Vice President of Research
  • Mr. Robert Sato M.B.A.
    Ph.D., Senior Vice President of Pharmaceutical Development, Quality & Regulatory

CDXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Codexis stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Codexis in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CDXS shares.
View CDXS analyst ratings
or view top-rated stocks.

What is Codexis' stock price target for 2024?

6 brokers have issued 12-month price objectives for Codexis' stock. Their CDXS share price targets range from $4.00 to $10.00. On average, they expect the company's stock price to reach $6.80 in the next year. This suggests a possible upside of 142.9% from the stock's current price.
View analysts price targets for CDXS
or view top-rated stocks among Wall Street analysts.

How have CDXS shares performed in 2024?

Codexis' stock was trading at $3.05 at the start of the year. Since then, CDXS shares have decreased by 8.2% and is now trading at $2.80.
View the best growth stocks for 2024 here
.

When is Codexis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our CDXS earnings forecast
.

How were Codexis' earnings last quarter?

Codexis, Inc. (NASDAQ:CDXS) released its quarterly earnings results on Wednesday, February, 28th. The biotechnology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.16) by $0.18. The biotechnology company had revenue of $26.56 million for the quarter, compared to analyst estimates of $24.73 million. Codexis had a negative trailing twelve-month return on equity of 47.58% and a negative net margin of 108.69%.

What ETF holds Codexis' stock?

Jacob Forward ETF holds 11,844 shares of CDXS stock, representing 1.17% of its portfolio.

What guidance has Codexis issued on next quarter's earnings?

Codexis issued an update on its FY 2024 earnings guidance on Wednesday, February, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $56.0 million-$64.0 million, compared to the consensus revenue estimate of $58.9 million.

What is John J. Nicols' approval rating as Codexis' CEO?

25 employees have rated Codexis Chief Executive Officer John J. Nicols on Glassdoor.com. John J. Nicols has an approval rating of 68% among the company's employees.

What other stocks do shareholders of Codexis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Codexis investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), AbbVie (ABBV), Micron Technology (MU), Enphase Energy (ENPH), Intellia Therapeutics (NTLA), NVIDIA (NVDA), OPKO Health (OPK) and Antares Pharma (ATRS).

How do I buy shares of Codexis?

Shares of CDXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CDXS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners